Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chase: Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer
NCT07555678Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in anal squamous cell carcinoma (SCCA), sponsored by Fudan University. Started Apr 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT07555678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555678.